Real-World Oncological Outcomes of Nivolumab Plus Ipilimumab in Advanced or Metastatic Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study in Japan

A combination of nivolumab and ipilimumab (NIVO + IPI) is the only approved combination of two immune checkpoint inhibitors for metastatic or advanced renal cell carcinoma (mRCC). Inadequate evidence of treatment with NIVO + IPI has been reported in Japanese cohorts. We evaluated the clinical effica...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Tomoki Taniguchi, Koji Iinuma, Kei Kawada, Takashi Ishida, Kimiaki Takagi, Masayuki Tomioka, Makoto Kawase, Kota Kawase, Keita Nakane, Yuki Tobisawa, Takuya Koie
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	MDPI AG 2024-12-01
श्रृंखला:	Current Oncology
विषय:	renal cell carcinoma nivolumab ipilimumab Japanese cohort
ऑनलाइन पहुंच:	https://www.mdpi.com/1718-7729/31/12/583
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!